Article Sidebar

PDF
Date Published: 08/06/2021
Abstract Views: 197
Views PDF: 169
DOI: https://doi.org/10.51298/vmj.v500i1.295
Issue
Vol. 500 No. 1 (2021)
Section
Các bài báo
How to Cite
Duy Thông, V. ., & Thị Thu Vân, B. . (2021). EFFICACY OF DIRECT-ACTING ANTIVIRUS AGENTS FOR THE PLATELET COUNT IMPROVEMENT IN CHRONIC HEPATITIS C VIRUS PATIENTS. Vietnam Medical Journal, 500(1). https://doi.org/10.51298/vmj.v500i1.295

EFFICACY OF DIRECT-ACTING ANTIVIRUS AGENTS FOR THE PLATELET COUNT IMPROVEMENT IN CHRONIC HEPATITIS C VIRUS PATIENTS

Võ Duy Thông, Bùi Thị Thu Vân

Main Article Content

Abstract

Objective: To investigate the efficacy of direct-acting antiviral drugs (DAAs) for the platelet count improvement in chronic hepatitis C patients. Methods: A retrospective cross-sectional study was conducted on 109 medical records of outpatients with chronic hepatitis C virus, treated at the Liver Clinic, University Medical Center HCMC from 01/2016 to 6/2020. Patients were indicated DAAs (without IFN or ribavirin) and platelet counts were tested before, during and 12 weeks after the end of treatment. Results: The mean age of patients was 58.3 ± 12.6, with a higher rate of women than men and patients without cirrhosis account for high rate. The platelet counts increased as early as 4 weeks after treatment and this increasement persisted at 12 weeks after treatment Grazoprevir/elbasvir, sofosbuvir/daclatasvir, and sofosbuvir/ledipasvir kept the platelet counts increasing after SVR attainment. Conclusion: DAAs are effective for the the platelet count improvement in chronic hepatitis C patients.

Article Details

Keywords

DAA, chronic hepatitis C virus, platelet count

References

1. Bộ Y Tế, Hướng dẫn chẩn đoán và điều trị viêm gan virus C (Ban hành kèm theo Quyết định số 5012/QĐ-BYT ngày 20/09/2016 của Bộ trưởng Bộ Y tế). 2016
2. Hoofnagle J. H. (1997). Hepatitis C: the clinical spectrum of disease. Hepatology (Baltimore, Md.), 26(3 Suppl 1), pp. 15S–20S.
3. Chen Y. C., Ko P. H., Lee C. C., Tseng C. W., & Tseng K. C. (2021). Baseline thrombopoietin level is associated with platelet count improvement in thrombocytopenic chronic hepatitis C patients after successful direct-acting antiviral agent therapy. BMC gastroenterology, 21(1), 30.
4. Gayam V., Mandal A. K., Khalid M., Mukhtar O., Gill A., Garlapati P., Khalid M., & Mansour M. (2018). Sofosbuvir Based Regimens in the Treatment of Chronic Hepatitis C with Compensated Liver Cirrhosis in Community Care Setting. International journal of hepatology, 2018, 4136253.
5. Chen Y. C., Tseng C. W., & Tseng K. C. (2020). Rapid platelet count improvement in chronic hepatitis C patients with thrombocytopenia receiving direct-acting antiviral agents. Medicine, 99(19), e20156.
6. Lý Thị Kim Dung. Khảo sát tình hình sử dụng và hiệu quả điều trị viêm gan siêu vi C mạn của thuốc kháng virus trực tiếp tại bệnh viện Đại học Y Dược TP. HCM. Luận văn thạc sĩ dược học, Trường Đại Học Y Dược TP. HCM. 2017.
7. Alcazer V., Miailhes P., Ramière C., Charre C. & Cotte L. (2018). Early sofosbuvir-ledipasvir treatment for acute HCV infection induced severe immune thrombocytopenia - a case report. BMC infectious diseases, 18(1), 682.
8. Seko Y., Moriguchi M., Takahashi A., Okishio S., Kataoka S., Okuda K., Mizuno N., Takemura M., Taketani H., Umemura A., Nishikawa T., Yamaguchi K., & Itoh Y. (2020). The Association between the Platelet Count and Liver Volume in Compensated Cirrhosis Patients after the Eradication of Hepatitis C virus by Direct-acting Antivirals. Internal medicine (Tokyo, Japan), 59(15), 1811–1817.